Korea Research Institute of Bioscience and Biotechnology

Bioneer Corporation

Soon Ja Choi

Kyung Seop Ahn

Sei Ryang Oh

Hyeong Kyu Lee

Jung Hee Kim

Han Oh Park

So Young Kim

Doo Young Kim

Mi Jin Kim

Gyoon Hee Han

Joong Ku Lee

Woo Seok Kim

Ok Kyoung Kwon

Bo Young Park

Sang Ku Lee

Gui Hua Quan

Byung Sun Min

Joo Heon Kim

Joo Sung Yang

Jung Joo Hong

Goo Taeg Oh

Woo Namkung

Seong Kyu Park

Guang Hai Shen

Gun Cheol Kim

Hea Young Park

Eun Ah Kim

Gui Hua Natural Medicines Research Center Quan

Gyoon Hee 209-1702 Sinyeongtong Hyundai Apt Han

San Ku Lee

The present invention relates to a dengue virus-specific siRNA, a double-stranded oligo RNA structure comprising the siRNA, and a composition for inhibiting dengue virus replication, which comprises the same, in which the double-stranded oligo RNA structure comprises a hydrophilic compound and hydrophobic compound conjugated to both ends of the double-stranded RNA (siRNA) by a single covalent bond or a linker-mediated covalent bond so that they will be efficiently delivered into cells, and can be converted into nanoparticles by hydrophobic interactions between the double-stranded oligo RNA structures in an aqueous solution. The siRNA included in the double-stranded oligo RNA structure acts specifically on all dengue virus serotypes. The present invention also relates to a method for preparing the double-stranded oligo RNA structure, and a pharmaceutical composition for preventing or treating dengue virus infection, which comprises the double-stranded oligo RNA structure.

Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure

The present invention relates to a composition comprising an extract of, and tiarellic acid isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract ofand the tiarellic acid isolated therefrom shows the inhibitory effect on the LTCrelease in vitro test and the suppressive effect on the IgE level and the cytokine (IL-4, IL-5 and IL-13) production, airway hyperresponsiveness, and leukocyte infiltration in OVA-induced asthmatic mice. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

[object Object]

This invention includes a composition ofand tilianin obtained by separation-purification for anti-inflammation and anti-atherosclerosis, and more particularly, an extract ofand tilianin obtained therefrom by separation-purification which are effective in preventing and treating not only inflammatory diseases but also atherosclerosis related to inflammatory responses and disease in the circulatory system caused by atherosclerosis because they are excellent in inhibiting the activity of complement systems as a factor of inflammatory responses, the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecular-1 (VCAM-1), and the production of nitric oxide (NO). They can also significantly reduce the development of atherosclerosis due to the inflammatory response.

Growing community of inventors

Daejeon, South Korea

Soon Ja Choi